| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
|
N Engl J Med
|
2014
|
6.73
|
|
2
|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
|
N Engl J Med
|
2015
|
5.69
|
|
3
|
High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone.
|
Leuk Lymphoma
|
2010
|
1.64
|
|
4
|
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.
|
Leuk Lymphoma
|
2014
|
1.47
|
|
5
|
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.
|
Blood
|
2008
|
1.46
|
|
6
|
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
|
Leuk Lymphoma
|
2010
|
1.41
|
|
7
|
Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era.
|
J Clin Oncol
|
2013
|
1.39
|
|
8
|
A case of systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma associated with hypereosinophilia, granulomatous myositis and vasculitis.
|
Leuk Lymphoma
|
2012
|
1.39
|
|
9
|
Predicting survival in chronic lymphocytic leukemia.
|
Expert Rev Anticancer Ther
|
2012
|
1.01
|
|
10
|
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.
|
Leuk Lymphoma
|
2013
|
0.85
|
|
11
|
Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
|
Leuk Lymphoma
|
2010
|
0.85
|
|
12
|
'Leukaemic' presentation of metastatic Merkel cell carcinoma.
|
Br J Haematol
|
2005
|
0.84
|
|
13
|
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2012
|
0.82
|
|
14
|
Venous thromboembolism prevention in patients undergoing colorectal surgery for cancer.
|
ANZ J Surg
|
2013
|
0.79
|
|
15
|
Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis.
|
Leuk Res
|
2007
|
0.77
|
|
16
|
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
|
Future Oncol
|
2015
|
0.77
|
|
17
|
High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
|
Leuk Lymphoma
|
2013
|
0.77
|
|
18
|
Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
|
Clin Infect Dis
|
2008
|
0.76
|
|
19
|
The infectious consequences of rituximab addition to fludarabine-containing regimens.
|
Blood
|
2006
|
0.76
|
|
20
|
Peripheral T cell and natural killer (NK) T cell lymphomas: a clinicopathological study from a single Australian centre.
|
Histopathology
|
2012
|
0.76
|
|
21
|
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
|
Eur J Haematol
|
2013
|
0.76
|
|
22
|
Association between early peak temperature and mortality in neutropenic sepsis.
|
Ann Hematol
|
2014
|
0.76
|
|
23
|
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
24
|
All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.
|
Eur J Haematol
|
2013
|
0.75
|
|
25
|
CD38 expression in CLL: a dynamic marker of prognosis.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
26
|
The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?
|
Leuk Lymphoma
|
2010
|
0.75
|
|
27
|
ABVD versus BEACOPP for Hodgkin's lymphoma.
|
N Engl J Med
|
2011
|
0.75
|
|
28
|
Chronic lymphocytic leukemia presenting as an intracranial epidural mass in a patient with myeloproliferative neoplasm associated with JAK2 V617F mutation.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
29
|
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosis.
|
Leuk Res
|
2007
|
0.75
|
|
30
|
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
|
Cancer
|
2006
|
0.75
|
|
31
|
New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.
|
Leuk Lymphoma
|
2010
|
0.75
|